InspireMD Launches Public Offering of Stock and Warrants Hours After FDA Win
NSPR sits 72% above its 52-week low of $0.425 on elevated volume (4.1× avg).
Summary
InspireMD kicked off a proposed public offering of common stock, pre-funded warrants and accompanying common warrants, with Lake Street Capital Markets as sole bookrunner. No size or pricing was disclosed, and the company said terms depend on market conditions. The timing is the story: it lands the same evening the FDA approved the CGuard Prime PMA supplement and Q3 results showed revenue down 11.1% with U.S. sales collapsing to $32K after the recall. InspireMD already carries a going concern warning and a $75M at-the-market program, so this is another equity raise into a $0.73 stock — dilution risk is the immediate overhang on today's regulatory win.
At the time of this announcement, NSPR was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.